Audentes Therapeutics (NASDAQ:BOLD) was downgraded by stock analysts at Guggenheim from a “buy” rating to a “neutral” rating in a report issued on Tuesday, The Fly reports.
Other research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. HC Wainwright reissued a “buy” rating and issued a $48.00 price target on shares of Audentes Therapeutics in a research note on Friday, November 8th. Chardan Capital restated a “buy” rating and issued a $50.00 price objective on shares of Audentes Therapeutics in a report on Sunday, October 6th. Robert W. Baird began coverage on shares of Audentes Therapeutics in a report on Wednesday, October 2nd. They issued an “underperform” rating and a $10.00 price objective on the stock. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $55.00 price objective on shares of Audentes Therapeutics in a research report on Friday, November 22nd. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $42.00.
NASDAQ BOLD opened at $28.61 on Tuesday. The stock has a fifty day simple moving average of $27.71 and a 200-day simple moving average of $33.11. The stock has a market cap of $1.33 billion, a PE ratio of -8.41 and a beta of 1.77. Audentes Therapeutics has a twelve month low of $17.95 and a twelve month high of $41.65.
Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.07. During the same quarter in the previous year, the business earned ($0.97) earnings per share. Analysts expect that Audentes Therapeutics will post -4.13 EPS for the current fiscal year.
In other Audentes Therapeutics news, Director Louis G. Lange sold 10,000 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $32.16, for a total transaction of $321,600.00. Following the sale, the director now directly owns 276,044 shares in the company, valued at approximately $8,877,575.04. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Matthew R. Patterson sold 14,426 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $30.00, for a total transaction of $432,780.00. Following the completion of the transaction, the chief executive officer now directly owns 127,820 shares of the company’s stock, valued at approximately $3,834,600. The disclosure for this sale can be found here. Insiders own 5.30% of the company’s stock.
Several institutional investors have recently bought and sold shares of BOLD. BlackRock Inc. raised its stake in shares of Audentes Therapeutics by 14.2% in the second quarter. BlackRock Inc. now owns 3,333,445 shares of the biotechnology company’s stock valued at $126,204,000 after acquiring an additional 413,768 shares in the last quarter. Great Point Partners LLC grew its stake in Audentes Therapeutics by 29.2% during the 3rd quarter. Great Point Partners LLC now owns 2,485,000 shares of the biotechnology company’s stock worth $69,804,000 after purchasing an additional 562,063 shares in the last quarter. Vanguard Group Inc. grew its stake in Audentes Therapeutics by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,971,206 shares of the biotechnology company’s stock worth $74,629,000 after purchasing an additional 84,659 shares in the last quarter. Victory Capital Management Inc. grew its stake in Audentes Therapeutics by 2.7% during the 2nd quarter. Victory Capital Management Inc. now owns 904,221 shares of the biotechnology company’s stock worth $34,233,000 after purchasing an additional 23,620 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in Audentes Therapeutics by 49.2% during the 3rd quarter. Millennium Management LLC now owns 773,279 shares of the biotechnology company’s stock worth $21,721,000 after purchasing an additional 255,086 shares during the period. 98.08% of the stock is currently owned by institutional investors and hedge funds.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Read More: Google Finance Portfolio
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.